|
|
||||||||
1 Department of Medicinal Chemistry, National Center for Natural Products Research, School of Pharmacy, University of Mississippi, University, Mississippi 38677-1848, USA
2 Department of Chemistry, University of Mississippi, University, Mississippi 38677-1848, USA
3 Department of Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California 94143-0811, USA
Reprint requests to: Mitchell A. Avery, 419 Faser Hall, Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, University, MS 38677-1848, USA; e-mail: mavery{at}olemiss.edu; fax: (662) 915-5638.
(RECEIVED August 9, 2002; FINAL REVISION November 19, 2002; ACCEPTED December 6, 2002)
Article and publication are at http://www.proteinscience.org/cgi/doi/10.1110/ps.0228103.
| Abstract |
|---|
|
|
|---|
Keywords: Plasmodium falciparum; falcipain; homology modeling; docking
| Introduction |
|---|
|
|
|---|
In P. falciparum, three papain-like cysteine proteases have been identified, characterized, and isolated thus far. Falcipain-1 was identified in erythrocytic parasites and found to hydrolyze hemoglobin (Salas et al. 1995). However, its low abundance and difficulties in developing expression systems have limited its study. Recently, two closely related cysteine proteases were identified and expressed. Falcipain-2 was shown to be one of the principal trophozoite cysteine proteases and hemoglobinases (Shenai et al. 2000), and more recently, falcipain-3 was identified in the acidic food vacuole of the parasite (Sijwali et al. 2001). Both proteases require a reducing environment and acidic pH for optimal activity. They differ, however, in that falcipain-3 undergoes efficient transformation into an active enzyme only at acidic pH. It is more active and stable at this pH with greater activity against native hemoglobin. Thus, falcipain-3 is the second P. falciparum hemoglobinase well suited for the hydrolysis of native hemoglobin in the food vacuole. It has been estimated that the concentration of falcipain-2 in trophozoites is 1.8 times that of falcipain-3; however, the latter appears to cleave native hemoglobin about twice as rapidly as the former. Thus, the relative contribution of the two enzymes to the hydrolysis of native hemoglobin is essentially equivalent, making falcipain-2 and falcipain-3 equally important targets for inhibition of hemoglobin degradation (Sijwali et al. 2001).
These findings imply that inhibitors of these enzymes could serve as potential leads for malarial chemotherapy. In fact, various studies have shown that inhibitors of falcipain-1 blocked the hydrolysis of globin and development of cultured parasites (Rosenthal et al. 1991, 1993, 1996; Ring et al. 1993; Olson et al. 1999). A few inhibitors of falcipain-2 have also been designed based on its homology model and shown to be active in vitro in the low micromolar range (Sabnis et al. 2002). Like falcipain-2, the crystal structure of falcipain-3 has yet to be elucidated. Homology modeling, based on sequence similarity among various proteins of the same family, offers a reasonable alternative for structure based drug design in such cases. Thus, to obtain a rational three-dimensional (3D) structure of falcipain-3, comparative protein structure modeling was employed. The resulting model was validated with various structure/geometry verification tools as well as docking studies of known substrates. The docking studies also provided insight into the possible binding modes and interactions of ligands with the enzyme.
| Results and discussion |
|---|
|
|
|---|
coordinates of these homologs was 0.72, indicating a strong structural conservation (Fig. 1
|
) angles mostly restricted to negative values and Psi (
) values clustered in a few distinct regions with 98% of residues occupying the allowed region. ProStat check for bond lengths, C-
chirality, amide torsion (
), Phi and Psi torsions for helices, Phi for Prolines and side chain torsions (
1 and
2) showed no major deviation from the corresponding allowed values. Only 3.2% of the total residues showed somewhat higher values (
5.0 standard deviations) for bond angles. However, none of these residues were part of the binding site. Profiles-3D (Lüthy et al. 1992) analysis suggested only one misfold across residues 7377. On further investigation it was realized that the average C-
distance of these residues from that of active site Cys51 was 16 Å and the minimum distance was 11 Å. Hence, this misfold was considered trivial. The overall self-compatibility score for the model was 86.99, as against a score of 45.55 or less, the latter would indicate an almost certainly incorrect structure. The secondary structure prediction by PSIPRED (Jones 1999; McGuffin et al. 2000) suggested five helices and six major strands with the remaining structure being predicted as coil. These results coincided with the secondary structure of the final model (Table 1
|
|
|
|
|
|
|
|
|
| Materials and methods |
|---|
|
|
|---|
Homology modeling
The falcipain-3 sequence (GenBank accession no. Q9NAW4) was obtained from the SWISS-PROT and TrEMBL databases of the ExPASy Molecular Biology Server (Bairoch and Apweiler 2000). Only the mature sequence (Fig. 1
) starting from residue Thr243, as per the numbering in the complete sequence (Sijwali et al. 2001), was considered in deriving the homology model. A WU-BLAST 2.0 (Gish 19962002) PDB search was performed on the mature falcipain-3 sequence with default parameters of BLASTP gapped alignment. We employed WU-BLAST 2.0 because the searches were more rapid than the ungapped version 1.4 programs, while using identical ungapped parameters. Crystal structures of cysteine proteases from various sources were identified as homologs for the query search. Only those sequences that passed the identity filter (>30%) and had a significance score of 21 or more were chosen as closely homologous to the query sequence and were retained for building the 3D model. This included homologs belonging to the hydrolase family of enzymes: cathepsin K (1ATK), cysteine protease from Zingiber officinale (1CQD), chymopapain from Carica papaya (1YAL), cruzain (1AIM and 1EWP) from Trypanosoma cruzi, and two theoretical models: leishmania cysteine protease from Leishmania major (1BMJ) and falcipain-2 from Plasmodium falciparum (Sabnis et al. 2002). Three different models were constructed. One based only on the crystal structures (Model 1) whereas, 1BMJ and falcipain-2 models were utilized in addition to the crystal structures to get the second (Model 2) and the third (Model 3) model, respectively. Profiles-3D predicted six misfolds for Model 1, one for Model 2 and five for Model 3. It was surprising to notice five misfolds for Model 3 because falcipain-2 model itself was not shown to have any misfolds. Further comparison of Model 1 and Model 2 revealed several important differences. Model 1 was shown to have 18 residues in the misfolded region compared to five residues in Model 2. This was also reflected in a lower Profiles-3D score (80.5) for Model 1 against 86.99 for Model 2. The phi-psi occupancy for Model 1 was 80% versus 98% for Model 2. Also, the energy as calculated by cvff forcefield for Model 1 was 490.01 kcal/mole compared to 410.9 kcal/mole for Model 2. RMSD of backbone atoms of the residues lining the binding pockets of Model 1 and Model 2 was found to be 0.6, whereas that for all backbone atoms was 2.02. These observations suggested that the conformation of binding pockets in both the models was quite similar, and hence, either of the models could be used for further studies. However, based on the overall folding and energy values as discussed above, it was decided to use Model 2 for all further studies.
The multiple sequence alignment among the template structures and the target sequence was performed against each of the homolog sequences using the method of Needleman and Wunsch (1970). Gaps were inserted into the sequences to find an optimal alignment, based on the length-independent gap penalty of 6. Initial sets of topologically equivalent residues in the reference proteins were used to generate an optimal structural alignment for the family of homologs. The resulting alignment was manually refined to optimize the matching of several characteristics including (a) conserved protease hydrophobic side chains and buried positions in the template structures, (b) functionally important sites such as the active site cysteine, and (c) insertions/deletions. Because the alignment and superposition of the six structures showed that the common fold began at Arg28 of the falcipain-3 sequence, the 27-residue N-terminus was not considered for building the model. Thus, the final model was built for 223 residues. Eleven SCRs were conceived based on this alignment and are shown in Figure 1
. Cruzain, having an overall percent identity of 35% and more than 80% in the SCRs with falcipain-3 (Fig. 1
), was chosen as a major contributor to derive coordinates for building the SCRs.
The last step in the generation of the 3D model was building the structurally variable regions (SVRs) or the loops onto the SCRs. The Tweak Loop (Shenkin et al. 1986Shenkin et al. 1987) approach was used to build loops onto the SCRs using the default parameters in COMPOSER. Different rotamers for the residues that line the active pocket were also studied and the most energy stable rotamer was retained.
Refinement
At this point, a theoretically reasonable model was constructed with a few trivial abnormalities, which were further corrected by minimization using the DISCOVER module of InsightII. The model was subjected to minimization for 2000 iterations of steepest descents followed by conjugate gradients, in two stages to a gradient of 0.001 kcal/mole/Å or less. In the first stage, the heavy atoms were tethered with a force constant of 100 kcal/Å, while in the second stage, the force constant was reduced to 75 kcal/Å. This protocol resolved all major geometrical defects with minimum deviation (RMSD 1.55 for heavy atoms) from the coarse model, as desired.
Docking
In the absence of reported inhibitors against falcipain-3, the homology model was validated by docking studies of various substrates for which the Km values were available. The substrates were built and minimized for 1000 steps each of steepest descents followed by conjugate gradients and finally by the BFGS method to a gradient of 0.001 kcal/mole/Å or less. The starting orientations were obtained by placing the substrates in the pocket surrounding Cys51 and intermolecular interaction energies were reduced to reasonable values by manual adjustments. The affinity docking was then performed by AFFINITY employing the cvff force field. Residues within 6 Å of the sulfur atom of the catalytic Cys51 were defined as the binding subset. Bulk of the protein, defined as atoms not in the binding subset, was held rigid during the docking process. Effect of solvent was introduced implicitly by solvation model of Stouten et al. (1993). First, 20 distinct docking poses of the substrates were collected using the Monte Carlo Minimization method, during which the ligands were subjected to random combinations of translational and rotational motions followed by minimization with 2500 iterations of conjugate gradients. Only those docking modes were retained wherein the ligands differed by a minimum RMS distance of 1 Å (RMS tolerance) and having an energy within 200 kcal (energy tolerance) of that of the lowest energy structure. During this stage the Quartic_vdw_no_Coul method was used to calculate energy. This choice employs a purely repulsive bounded quartic potential for modeling VDW interactions, and Coulombic interactions are set to zero. In the second stage, a more refined Cell-multipole method (Greengard and Rokhlin 1987) for calculation of nonbonded interactions was utilized. Here the structures so obtained were refined by minimization for 100 steps of conjugate gradients followed by a dynamics run for 5000 iterations of equilibration at 300 K. The Newtons equations of motion were integrated using the Verlet Algorithm (Verlet 1967) with a time step of 1 fs using NVT ensemble. Temperature control was achieved by direct scaling of atom velocities. Finally, the structures were minimized to a gradient of 0.001 kcal/mole/Å or less using conjugate gradients. The same protocol was also employed for the docking of these substrates in the falcipain-2 homology model. The various docking poses of each substrate were ranked based on the empirical interaction energies between the substrate and the enzyme. The one with the lowest interaction energy was selected for further analysis.
| Conclusions |
|---|
|
|
|---|
The falcipain-3 model offers a promising opportunity to design and develop novel inhibitors that could block one of the major mediators of hemoglobin denaturation. However, effective blockade of parasite development by suppression of parasite hemoglobin hydrolysis would likely require a potent inhibition of both falcipain-3 and falcipain-2. Comparison of the binding pockets of falcipain-3 with that of falcipain-2 model suggested some interesting features relevant to the drug design process. Some differences in the residues lining the S2 pockets of these enzymes were observed leading to a narrower S2 pocket in falcipain-3. Although, this difference may affect the ligand interaction to some extent, overall similarity of the binding pockets of these enzymes does not rule out the possibility of development of ligands with dual inhibition of falcipain-2 and falcipain-3. In any event, the proposed falcipain-3 model could be used to direct structure-based drug design studies leading to development of chemotherapeutic agents to combat malaria.
| Acknowledgments |
|---|
The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.
| References |
|---|
|
|
|---|
Breman, J.G. 2001. The ears of the hippopotamus: Manifestations, determinants, and estimates of the malaria burden. Am. J. Trop. Med. Hyg. 64: 111.[Abstract]
Brinen, L.S., Hansell, E., Cheng, J., Roush, W.R., McKerrow, J.H., and Fletterick, R.J. 2000. A target within the target: Probing cruzains P1 site to define structural determinants for the Chagas disease protease. Structure 8: 831840.[Medline]
Butler, D., Maurice, J., and OBrien, C. 1997. Time to put malaria control on the global agenda. Nature 386: 535536.[CrossRef][Medline]
Choi, H.K., Laursen, R.A., and Allen, K.N. 1999. The 2.1 Å structure of a cysteine protease with proline specificity from ginger rhizome, Zingiber officinale. Biochemistry 38: 1162411633.[CrossRef][Medline]
Edsall, J.T., Flory, P.J., Liquori, A.M., Kendrew, J.C., Nemethy, G., Ramachandran, G.N., and Scheraga, H.A. 1966. A proposal of standard conventions and nomenclature for the description of polypeptide conformation. Biopolymers 4: 121129.
Eggleson, K.K., Duffin, K.L., and Goldberg, D.E. 1999. Identification and characterization of falcilysin, a metallopeptidase involved in hemoglobin catabolism within the malaria parasite Plasmodium falciparum. J. Biol. Chem. 274: 3241132417.
Folkers, G. 1998. Integrated homology modeling and X-ray study of herpes simplex virus I thymidine kinase. In Structure-based rug design experimental and computational approaches (ed. P.W. Codding), pp. 271283. Kluwer Academic Publishers, Norwell, MA, USA.
Francis, S.E., Gluzman, I.Y., Oksman, A., Knickerbocker, A., Mueller, R., Bryant, M.L., Sherman, D.R., Russell, D.G., and Goldberg, D.E. 1994. Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase. EMBO J. 13: 306317.[Medline]
Gillmor, S.A., Craik, C.S., and Fletterick, R.J. 1997. Structural determinants of specificity in the cysteine protease cruzain. Protein Sci. 6: 16031611.[Abstract]
Gish, W. WU-BLAST archives. 19962002. http://blast.wustl.edu.
Godzik, A., Kolinski, A., and Skolnick, J. 1992. Topology finger print approach to the inverse protein folding problem. J. Mol. Biol. 227: 227238.[CrossRef][Medline]
Goldberg, D.E. 2002. Parasitology: When the host is smarter than the parasite. Science 296: 482483.
Greengard, L. and Rokhlin, V.I. 1987. A fast algorithm for particle simulations. J. Comp. Phys. 73: 325348.[CrossRef]
Jones, D.T. 1999. Protein secondary structure prediction based on position-specific scoring matrices. J. Mol. Biol. 292: 195202.[CrossRef][Medline]
Klemba, M. and Goldberg, D.E. 2002. Biological roles of proteases in parasitic protozoa. Annu. Rev. Biochem. 71: 275305.[CrossRef][Medline]
Leung, D., Abbenante, G., and Fairlie, D.P. 2000. Protease inhibitors: Current status and future prospects. J. Med. Chem. 43: 305341.[CrossRef][Medline]
Lüthy, R., Bowie, J.U., and Eisenberg, D. 1992. Assessment of protein models with three-dimensional profiles. Nature 356: 8385.[CrossRef][Medline]
Luty, B.A., Wasserman, Z.R., Stouten, P.F.W., Hodge, C.N., Zacharias, M., and McCammon, J.A. 1995. A molecular mechanics/grid method for evaluation of ligand-receptor interactions. J. Comp. Chem. 16: 454464.[CrossRef]
Maes, D., Bouckaert, J., Poortmans, F., Wyns, L., and Looze, Y. 1996. Structure of chymopapain at 1.7 A resolution. Biochemistry 35: 1629216298.[CrossRef][Medline]
McGuffin, L.J., Bryson, K., and Jones, D.T. 2000. The PSIPRED protein structure prediction server. Bioinformatics 16: 404405.
Needleman, S. and Wunsch, C. 1970. A general method applicable to the search for similarities in the amino acid sequence of two proteins. J. Mol. Biol. 48: 443453.[CrossRef][Medline]
Olliaro, P.L. and Yuthavong, Y. 1999. An overview of chemotherapeutic targets for antimalarial drug discovery. Pharm. Ther. 81: 91110.[CrossRef][Medline]
Olson, J.E., Lee, G.K., Semenov, A., and Rosenthal, P.J. 1999. Antimalarial effects in mice of orally administered peptidyl cysteine protease inhibitors. Bioorg. Med. Chem. 7: 633638.[CrossRef][Medline]
Ring, C.S., Sun, E., McKerrow, J.H., Lee, G.K., Rosenthal, P.J., Kuntz, I.D., and Cohen, F.E. 1993. Structure-based inhibitor design by using protein models for the development of antiparasitic agents. Proc. Natl. Acad. Sci. 90: 35833587.
Rosenthal, P. 1998. Proteases of malaria parasites: New targets for chemotherapy. Emerg. Infect. Dis. 4: 4956.[Medline]
Rosenthal, P.J. 2002. Hydrolysis of erythrocyte proteins by proteases of malaria parasites. Curr. Opin. Hematol. 9: 140145.[CrossRef][Medline]
Rosenthal, P.J. and Meshnick, S.R. 1996. Hemoglobin catabolism and iron utilization by malaria parasites. Mol. Biochem. Parasitol. 83: 131139.[CrossRef][Medline]
Rosenthal, P.J., Wollish, W.S., Palmer, J.T., and Rasnick, D. 1991. Antimalarial effects of peptide inhibitors of a Plasmodium falciparum cysteine proteinase. J. Clin. Invest. 88: 14671472.
Rosenthal, P.J., Lee, G.K., and Smith, R.E. 1993. Inhibition of a Plasmodium vinckei cysteine proteinase cures murine malaria. J. Clin. Invest. 91: 10521056.
Rosenthal, P.J., Olson, J.E., Lee, G.K., Palmer, J.T., Klaus, J.L., and Rasnick, D. 1996. Antimalarial effects of vinyl sulfone cysteine proteinase inhibitors. Antimicrob. Agents Chemother. 40: 16001603.[Abstract]
Sabnis, Y., Rosenthal, P.J., Desai, P., and Avery, M.A. 2002. Homology modeling of falcipain-2: Validation, de novo ligand design and synthesis of novel inhibitors. J. Biomol. Struct. Dyn. 19: 765774.[Medline]
Sajid, M. and McKerrow, J.H. 2002. Cysteine proteases of parasitic organisms. Mol. Biochem. Parasitol. 120: 121.[CrossRef][Medline]
Salas, F., Fichmann, J., Lee, G.K., Scott, M.D., and Rosenthal, P.J. 1995. Functional expression of falcipain, a Plasmodium falciparum cysteine proteinase, supports its role as a malarial hemoglobinase. Infect. Immun. 63: 21202125.[Abstract]
Selzer, P.M., Chen, X., Chan, V.J., Cheng, M., Kenyon, G.L., Kuntz, I.D., Sakanari, J.A., Cohen, F.E., and McKerrow, J.H. 1997. Leishmania major: Molecular modeling of cysteine proteases and prediction of new nonpeptide inhibitors. Exp. Parasitol. 87: 212221.[CrossRef][Medline]
Shenai, B.R., Sijwali, P.S., Singh, A., and Rosenthal, P.J. 2000. Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of Plasmodium falciparum. J. Biol. Chem. 275: 2900029010.
Shenkin, P.S., Yarmush, D.L., Fine, R.M., Wang, H., and Levinthal, C. 1986. Predicting antibody hypervariable loop conformations II: Minimization and molecular dynamics studies of MCPC603 from many randomly generated loop conformations. Proteins Struct. Funct. Genet. 1: 342362.[CrossRef][Medline]
. 1987. Predicting antibody hypervariable loop conformation. I. Ensembles of random conformations for ringlike structures. Biopolymers 26: 20532085.[CrossRef][Medline]
Sijwali, P.S., Shenai, B.R., Gut, J., Singh, A., and Rosenthal, P.J. 2001. Expression and characterization of the Plasmodium falciparum hemoglobinase falcipain-3. Biochem. J. 360: 481489.[CrossRef][Medline]
Stouten, P.F.W., Froemmel, C., Nakamura, H., and Sander, C. 1993. An effective solvation term based on atomic occupancies for use in protein simulations. Mol. Simul. 10: 97120.
Verlet, L. 1967. Computer "experiments" on classical fluids. I. Thermodynamical properties of Lennard-Jones molecules. Phys. Rev. 159: 98103.[CrossRef]
Zhao, B., Janson, C.A., Amegadzie, B.Y., DAlessio, K., Griffin, C., Hanning, C.R., Jones, C., Kurdyla, .J., McQueney, M., Qiu, X., et al. 1997. Crystal structure of human osteoclast cathepsin K complex with E-64. Nat. Struct. Biol. 4: 109111.[CrossRef][Medline]
![]()
CiteULike
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
H.-Y. Yoon, K. Miura, E. J. Cuthbert, K. K. Davis, B. Ahvazi, J. E. Casanova, and P. A. Randazzo ARAP2 effects on the actin cytoskeleton are dependent on Arf6-specific GTPase-activating-protein activity and binding to RhoA-GTP J. Cell Sci., November 15, 2006; 119(22): 4650 - 4666. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Oji, J. M. Hautier, B. Ahvazi, I. Hausser, K. Aufenvenne, T. Walker, N. Seller, P. M. Steijlen, W. Kuster, A. Hovnanian, et al. Bathing suit ichthyosis is caused by transglutaminase-1 deficiency: evidence for a temperature-sensitive phenotype Hum. Mol. Genet., November 1, 2006; 15(21): 3083 - 3097. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Omara-Opyene, P. A. Moura, C. R. Sulsona, J. A. Bonilla, C. A. Yowell, H. Fujioka, D. A. Fidock, and J. B. Dame Genetic Disruption of the Plasmodium falciparum Digestive Vacuole Plasmepsins Demonstrates Their Functional Redundancy J. Biol. Chem., December 24, 2004; 279(52): 54088 - 54096. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Benson, H. A. Pershadsingh, C. I. Ho, A. Chittiboyina, P. Desai, M. Pravenec, N. Qi, J. Wang, M. A. Avery, and T. W. Kurtz Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPAR{gamma}-Modulating Activity Hypertension, May 1, 2004; 43(5): 993 - 1002. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |